Seattle Genetics News

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the appointment of Bruce J. Seeley as Senior Vice President & General Manager, Diagnostics.

During the past five sessions, traders on the International Securities Exchange and Chicago Board Options Exchange have bought to open 2,334 calls on the biotech stock, along with just 96 puts.

BOTHELL, Wash.-- --Seattle Genetics, Inc. announced today that the validation period is complete and Health Canada has accepted for review its New Drug Submission for the use of ADCETRIS in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma .

An experimental breast cancer drug being developed by tiny Celldex Therapeutics of Needham., Mass., appeared to show a potent tumor-shrinking effect in four women who had both an especially hard-to-treat form of breast cancer and whose tumors had high levels of the protein targeted by the drug.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Sometimes when a drug hits the market, it can take on a life of its own.

's stock had its "neutral" rating restated by equities researchers at UBS AG in a report issued on Friday.

BOTHELL, Wash. -- -- Seattle Genetics, Inc. today announced that data from two of its antibody-drug conjugate programs, ADCETRIS and ASG-5ME, will be presented at the American Society of Clinical Oncology 2012 Annual Meeting being held June 1-5, 2012 in Chicago, IL.

BOTHELL, Wash. -- -- Seattle Genetics, Inc. announced today that management will present at the Bank of America Merrill Lynch 2012 Health Care Conference on Tuesday, May 15, 2012 at 1:00 p.m. Pacific Time.

BOTHELL, Wash. -- -- Seattle Genetics, Inc. today announced that interim results from an investigator-sponsored phase II clinical trial of ADCETRIS in patients with relapsed cutaneous T-cell lymphoma were presented at the Society for Investigative Dermatology annual meeting being held May 9-12, 2012 in Raleigh, NC.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Shares of the following companies may have unusual moves in U.S. trading tomorrow.

BOTHELL, Wash. -- -- Seattle Genetics, Inc. today reported financial results for the first quarter ended March 31, 2012.

Millennium: The Takeda Oncology Company, of Cambridge and Seattle Genetics Inc. of Bothell, Wash., said today that they have started a Phase 3 clinical trial to evaluate Adcetris, a drug candidate they are jointly developing for patients with CD30-expressing relapsed cutaneous T-cell lymphoma.

In this position he will lead the company's newly created clinical development operations based in .

In this article, I will cover some catalyst trades with the primary focus being on MediciNova .